copiktra

Infinity Pharmaceuticals and Abbvie collaborated to develop and commercialize duvelisib, an evolutionary cancer therapy offering an oral, dual P13K inhibitor that delivers the power of combination therapy in a single pill. To develop a brand name for them, Brandsymbol wanted to highlight the power of a combination therapy in a single pill. The chosen name, Copiktra, highlights many of the creative cues Abbvie and Infinity wanted to accentuate. The prefix “co” has a dual meaning, alluding to courage, as well as the combination therapy, “pik” refers to the PI3K oral inhibitor, and “tra” comes from transformational.